Raffa Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.45K Hold
60
– – ﹤0.01% 463
2026
Q2
$7.36K Hold
60
– – ﹤0.01% 502
2026
Q1
$6.32K Hold
60
– – ﹤0.01% 484
2025
Q4
$5.24K Hold
60
– – ﹤0.01% 512
2025
Q3
$3.99K Hold
60
– – ﹤0.01% 529
2025
Q2
$3.32K Buy
+60
New +$2.88K ﹤0.01% 582

Other funds holding PTGX

Raffa Wealth Management's PTGX Position: Q3 2026 in Review

Raffa Wealth Management held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 60 shares worth $8.45K. The position accounts for ﹤0.01% of the portfolio, ranked #463.

Raffa Wealth Management first reported a position in PTGX in Q2 2025 and has held it in 6 quarters since. 368 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Raffa Wealth Management held 60 shares of Protagonist Therapeutics worth $8.45K as of Q3 2026.
  • Raffa Wealth Management left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Raffa Wealth Management's portfolio in Q3 2026, its #463 holding.
  • Raffa Wealth Management first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 368 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Raffa Wealth Management's 13F filing for Q3 2026, filed 16 Nov 2026.